Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $74.49 and last traded at $71.53, with a volume of 315873 shares traded. The stock had previously closed at $68.21.
Neoleukin Therapeutics Stock Down 0.9 %
The business’s 50 day simple moving average is $47.15 and its 200 day simple moving average is $40.24. The stock has a market cap of $372.72 million, a price-to-earnings ratio of -12.86 and a beta of 1.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
See Also
- Five stocks we like better than Neoleukin Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Rocket Lab is the Right Stock for the Right Time
- What Are Dividend Challengers?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- What Do S&P 500 Stocks Tell Investors About the Market?
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
